Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma
View
Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
View
Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Biliary Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Title:
Registry study with Breast Cancer Index
View
Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)
View
Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- MBC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
View
Description: D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02).
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma
View
Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)
Indication:
Carcinoid
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph2 Epidemi Colon Cancer
View
Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
Ph2 RO7198457 CRC ctDNA+ Post Resection
View
Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST
View
Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Colon Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
INCMGA00012 Endo Cancer
View
Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST
View
Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)
Indication:
Esophageal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Esophageal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
View
Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
View
Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST
View
Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Gastric Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
View
Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST
View
Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Hematologic
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Leukemia
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Liver Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Biomarker status NSCLC
View
Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
View
Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC
View
Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
Ph2 Epco r/r B-Cell Lymph out pt
View
Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)
Indication:
Lymphomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Melanoma
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
Ph2 Dara Lena Dexa (DRd) MM I
View
Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
Ph3 Sub VS Inta Isatu +Poma Dexa r/r MM
View
Description: A randomized Phase 3 open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM) (EFC15951)
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Myelomas
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST
View
Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
View
Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA)
View
Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
Ph2 Epidemi Colon Cancer
View
Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
Ph2 RO7198457 CRC ctDNA+ Post Resection
View
Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Rectal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Renal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Skin Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C
View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST
View
Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: I/II
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Solid Tumors
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: IV
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Urothelial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: II/III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: I